Royalty Pharma (RPRX) Non-Current Assets (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Non-Current Assets data on file, last reported at $18.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 16.65% year-over-year to $18.4 billion; the trailing twelve-month figure through Mar 2026 stood at $70.8 billion (up 11.45% YoY), and the FY2025 full-year result was $18.1 billion, up 10.18% from the prior year.
• Non-Current Assets rose to $18.4 billion in Q1 2026, from $18.1 billion in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $18.4 billion in Q1 2026 to a low of $14.1 billion in Q3 2023.
• A 5-year average of $15.6 billion and a median of $15.1 billion in 2023 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets slipped 7.85% in 2023 and increased 16.65% in 2026, its largest moves.
• Tracing RPRX's Non-Current Assets over 5 years: stood at $14.3 billion in 2022, then gained by 5.96% to $15.1 billion in 2023, then gained by 8.69% to $16.4 billion in 2024, then rose by 10.18% to $18.1 billion in 2025, then grew by 1.64% to $18.4 billion in 2026.
• Business Quant data shows RPRX's Non-Current Assets at $18.4 billion in Q1 2026, $18.1 billion in Q4 2025, and $17.5 billion in Q3 2025.